Previous Section Index Home Page


HEALTH

Passported Benefits

Ms Buck: To ask the Secretary of State for Health what would be the cost of designating recipients of tax credits

26 Apr 1999 : Column: 22

and their families as people entitled to passported benefits under the National Health Service (Travelling Expenses and Remission of Charges) Regulations 1988. [69748]

Mr. Denham: The additional costs (compared with the current passporting of Family Credit and Disability Working Allowance) are (for England) estimated to be £48 million in 1999-2000, £113 million in 2000-01 and £125 million in 2001-02 in total in respect of National Health Service prescriptions, NHS dental treatment, NHS sight tests and optical vouchers. Costs in respect of wigs and fabric supports and patients' travel hospital expenses would also be incurred by NHS trusts.

Lamotrigine

Mr. Lock: To ask the Secretary of State for Health, pursuant to his answer of 30 March 1999, Official Report, columns 656-57, on Lamotrigine, if he will list for each of the 35 inquiries referred to (a) the incident or event which gave rise to the inquiry, (b) the name and address of the person who generated the inquiry, (c) details of the nature of the inquiry and (d) the steps which (i) his Department and (ii) the Medicines Control Agency have taken in response to the inquiry. [80231]

Mr. Denham [holding answer 13 April 1999]: Details of the 35 inquiries received by the Medicines Control Agency relating to lamotrigine from health professionals and members of the public since the marketing authorisation was granted are shown in the table. In many cases, the incident or event which gave rise to the inquiry is not known. Under the Data Protection Act the names and addresses of the inquirers have been withheld and cannot be provided without the written permission of the individuals concerned. In most cases, the nature of the inquiries was to seek information on adverse drug reactions to lamotrigine, which is routinely provided on request to health professionals and members of the public by the Medicines Control Agency.

Inquiries relating to lamotrigine received by the Medicines Control Agency up to April 1999

Reason for inquiryInquirerNature of inquiry (information requested)Response
Not knownDoctorInformation on reduced white blood cell count with carbamazepine and lamotrigineDrug Analysis Prints(1) (DAPs) provided
A patient with hair lossDoctorInformation on hair loss with lamotrigineDAP and details of reports of hair loss provided
An ADR reporting studyDoctorInformation on ADR reports in the Grampian Region for citalopram, gabapentin, lamotrigine, moclobemide, nefazodone, tramadol, venlafazine, topiramate and fentanyl patchesDetails of reports provided
A pathologist had carried out an autopsy on patient who had taken lamotrigineDoctorInformation on deaths reported in association with lamotrigineDAP and details of fatal reports provided
Not knownDoctorInformation on ADRs with lamotrigine (particularly aggression)DAP provided
Not knownPharmacistInformation on ADRs to lamotrigine (particularly liver reactions)DAP provided
The doctor was reporting a patient with dizziness and vomiting on lamotrigineDoctorInformation on ADRs to lamotrigineDAP provided
The inquirer was editing a textbookDoctorInformation related to psychiatric ADRs with gabapentin, lamotrigine, vigabatrin, topiramate, clobazam and felbamateDAP provided
Not knownDoctorInformation on ADRs with lamotrigineDAP provided
Not knownDoctorInformation on ADRs with lamotrigineDAP provided
The inquirer was carrying out research on ADRs with antiepilepticsDoctorInformation on ADRs with lamotrigine, vigabatrin, gabapentinDAPs provided
The inquirer needed information for a court reportDoctorInformation on cases of aggression, agitation, confusion, personality change and restlessnessInformation on reports provided
Not knownPharmacistInformation on ADRs with lamotrigineDAP provided
Not knownDoctorInformation on yellow macular pigment with carbamazepine and lamotrigineDAPs provided
Not knownDoctorInformation on uveitis with lamotrigine and sodium valproateDAPs provided
Not knownPharmacistInformation on lamotrigine and carbamazepine and ecchymoses and capillary fragilityDAPs provided
Not knownDoctorInformation on ADRs with lamotrigineDAP provided
Not knownPharmacistInformation on lamotrigine and hormone replacement therapy when used togetherDAPs provided
Concern over press coverage of lamotrigine and skin reactionsDoctorFurther information requestedInformation provided over telephone
Not knownPharmacistInformation on pruritus and rashes with lamotrigineDAP provided
Not knownPharmacistInformation on gastrointestinal blockage vigabatrin, carbamazepine and lamotrigineDAPs provided
Two patients on sodium valproate developed thrombocytopenia when lamotrigine was addedPharmacistInformation on any other reports involving sodium valproate and lamotrigineDetails of relevant reports provided
Not knownPharmacistInformation on visual hallucinations with lamotrigineDAP and details of reports provided
Not knownDoctorInformation on hypogammaglobinaemia with lamotrigine and vigabatrinDAPs provided
Not knownPharmacistInformation on urinary incontinence with lamotrigineDAPs provided
Not knownPharmacistInformation on ADRs with lamotrigineDAP provided
Not knownDoctorInformation on ADRs with gabapentin, vigabatrin and lamotrigineDAPs provided
Not knownPharmacistInformation on raised liver enzymes with lamotrigineDAP provided
Not knownPharmacistInformation on ADRs with lamotrigine and haloperidolDAPs provided
Not knownPharmacistInformation on ADRs indomethacin and diclofenacDAPs provided
Not knownDoctorInformation on psychiatric ADRs with lamotrigineDAP provided
Issue of skin reactionsRegulatory authorityInformation on serious skin reactions with amotrigineDetails of reports provided
Not knownMember of the publicInformation on ADRs with lamotrigineDAP provided
Confusion over the brand names Lamicta and LamasilGP Practice ManagerInquiry as to whether there was a list of drugs with similar names which could cause confusionNo such list was known
Parliamentary questionMartin Redmond MPWhat research his Department has carried out into a comparison of lamotrigine and valproate monotherapy in patients with primary generalised seizures; with what findingsHansard reference 263 c922-3W

(1) A Drug Analysis Print (DAP) gives a complete list of all suspected adverse reactions reported through the Yellow Card Scheme to the Committee on Safety of Medicines (CSM)/Medicines Control Agency (MCA) in association with the named drug substance.


26 Apr 1999 : Column: 25

NHS Pay

Mr. Laurence Robertson: To ask the Secretary of State for Health what estimate he has made of the cost to the Gloucestershire Health Authority of the pay award to all NHS employees for 1999-2000. [80401]

Mr. Denham [holding answer 13 April 1999]: Gloucestershire Health Authority, working closely with local National Health Service trusts, estimate that £6.6 million will be required to meet the costs of the pay award for NHS employees for 1999-2000. Pay awards for certain staff groups have yet to be announced.

Biggleswade and Steppingley Hospitals

Mr. Sayeed: To ask the Secretary of State for Health what proportion of the patient base at Biggleswade and Steppingley hospitals is comprised of people originating outside Mid-Bedfordshire. [80476]

Mr. Denham: The information requested is not normally available centrally; however, I am informed by the health authority that at Biggleswade Hospital, of the 20 admissions over the past two months 10 have been for patients outside the Mid-Bedfordshire area. At Steppingley Hospital, 8 out of the 27 patients admitted within the last two months were from out of the Mid-Bedfordshire area.

Speech Therapists

Mr. Cotter: To ask the Secretary of State for Health what has been the salary increase for speech therapists in the NHS in each of the last five years (a) in real terms and (b) as a percentage. [81065]

26 Apr 1999 : Column: 26

Mr. Denham [holding answer 16 April 1999]: The information requested is in the table.

Speech and language therapists' pay settlements 1994-98

YearTotal increase per cent.
1994 -952.4Paid in full from 1 April: 0.1 per cent. in real terms.
1995 -963.0Paid as 1 per cent. national from 1 April 1995. Further 2 per cent. paid as local settlement: 0.4 per cent. in real terms.
1996 -972.8Paid as 2 per cent. national from 1 April 1996 and further 0.8 per cent. as average local pay settlement:--0.1 per cent. in real terms.
1997 -983.3Paid as 2 per cent. from 1 April 1997 and further 1.3 per cent. from 1 December: 0.8 per cent. in real terms.
1998 -993.8Paid as 2 per cent. from 1 April 1998 and further 1.8 per cent. from 1 December: 0.8 per cent. in real terms.

Source:

Pay Increase:--Advance Letters (increase to basic salary for all grades). RPI(X): Office for National Statistics (rate, excluding mortgage rates, in April each year, starting in April 1994 and ending in April 1998).



Next Section Index Home Page